CLINUVEL (ASX:CUV) has announced final results from its Phase 2 pilot study evaluating SCENESSE (afamelanotide) as a monotherapy in patients with the depigmentation disorder vitiligo. …
Pilot study confirms adjunct NB-UVB needed to activate repigmentation in vitiligo
June 18, 2025 Australian Biotech
Latest Video
New Stories
-
Pilot study confirms adjunct NB-UVB needed to activate repigmentation in vitiligo
June 18, 2025 - - Australian Biotech -
Montu pushes for national standards at Productivity Commission inquiry
June 17, 2025 - - Latest News -
Canadian appointed to lead New Zealand's Pharmac
June 17, 2025 - - Latest News -
US FDA approves CSL's treatment for hereditary angioedema
June 17, 2025 - - Latest News -
Australia's system is more uniform than the US, but not uniformly better
June 17, 2025 - - Latest News -
Australian company secures FDA approval to progress development of CAR-T therapy
June 16, 2025 - - Latest News -
These systems are and always have been more similar than most realise
June 16, 2025 - - Latest News